跳至主要内容
临床试验/JPRN-UMIN000034387
JPRN-UMIN000034387
已完成
未知

ong-term renoprotective effect of SGLT2 inhibitors - Renoprotection by SGLT2 inhibitors

ephrology Division, JA Toride Medical Center0 个研究点目标入组 60 人2018年11月1日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
type 2 diabetes melllitus
发起方
ephrology Division, JA Toride Medical Center
入组人数
60
状态
已完成
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2018年11月1日
结束日期
2018年11月30日
最后更新
2年前
研究类型
Observational
性别
All

研究者

发起方
ephrology Division, JA Toride Medical Center

入排标准

入选标准

  • 未提供

排除标准

  • nothing particular

结局指标

主要结局

未指定

相似试验

已完成
3 期
Evaluation Renoprotective Effect SGLT2 inhibitors on Prognosis of Transplant Kidney PatientsCondition 1: Diabetes mellitus type 2. Condition 2: Transplant Kidney.Type 2 diabetes mellitus with kidney complicationsKidney transplant statusE11.2Z94.0
IRCT20220708055414N1Orchidpharmed30
招募中
2 期
Comparison of the renoprotective effects of SGLT2 inhibitor (Empagliflozin) in diabetic and non-diabetic kidney transplantation patients
IRCT20130812014333N168Kermanshah University of Medical Sciences28
进行中(未招募)
1 期
The RECEDE-CHF TrialType 2 diabetes and heart failureMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2016-003968-39-GBniversity of Dundee/NHS Tayside23
招募中
不适用
The Renal Protective Effect Of SGLT2 Inhibitor Drug In Diabetics Patient Who Are Undergoing Per cutaneous Coronary Interventions.Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications
CTRI/2023/10/058896GSM Institute of Pharmaceutical Science
Unknown
4 期
Effect of SGLT2 inhibitor on Renal Function and Urinary [TIMP-2] x [IGFBP7] in Patients Hospitalized for Acute Heart Failure; A Randomized Controlled TrailAcute kidney injury and urinary [TIMP-2] x [IGFBP7] in patient hospitalized for acute heart failureAcute kidney injury, urinary [TIMP-2] x [IGFBP7], nephrocheck, acute heart failure, acute decompensated heart failure, SGLT2 inhibitor, renal function, biomarker
TCTR20221003002/A66